Identification of SARS-CoV-2 entry inhibitors among already approved drugs.
Journal Information
Full Title: Acta Pharmacol Sin
Abbreviation: Acta Pharmacol Sin
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Conflict of interest The authors declare that they have no conflict of interest."
Funding Disclosure
Evidence found in paper:
"This work was supported by the National Key Research and Development Program of China (2018YFC1200604). Experiments related to SARS-CoV-2 were carried out at the National Biosafety Laboratory, Wuhan, Chinese Academy of Sciences. We are particularly grateful to Tao Du and Lun Wang from the Zhengdian Biosafety Level 3 Laboratory and the team running the laboratory for their work. The pNL4.3.Luc.R-.E- plasmid was kindly gifted by Dr Shi-bo Jiang and Dr Lu Lu from Fudan University."
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025